Navigation Links
B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
Date:3/31/2009

Integrated Solution's Electronic Health Record Capability Highlighted

BETHLEHEM, Pa., March 31 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun) said its Outlook(R) Safety Infusion System, DoseTrac(TM) Infusion Management Software and DoseLink(TM) Interfaces successfully completed applicable portions of the Healthcare Information Technology Standards Panel's (HITSP) federally recognized Interoperability Specifications test at the Integrating the Healthcare Enterprise 2009 Connectathon in Chicago in February.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

The Connectathon is the healthcare information technology (IT) industry's largest interoperability testing event. More than 130 healthcare IT systems were tested by the nearly 70 vendors present.

"This is a critical achievement for B. Braun," said Scott Zaffrin, Manager, Infusion Systems Connectivity for B. Braun Medical Inc. "The emphasis in healthcare today, within the industry and the Obama Administration, is on developing integrated healthcare systems that interface with other systems and have the ability to transmit patient information electronically to reduce errors and deliver more effective treatment to patients. Our suite of infusion system products is designed to do just that."

B. Braun will demonstrate the Outlook(R), '/>"/>

SOURCE B. Braun Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
(Date:3/2/2015)... Surgeons at the Forbes Hospital ... Network, are exploring an innovative use of Google ... Zonal Reminder (VIZR), to assist in the care of ... is a wearable technology with an optical head-mounted display ... communicate with the Internet via natural language voice commands. ...
(Date:3/2/2015)... March 02, 2015 Ticket Down is ... the Hollywood Bowl . This popular site has reduced ... promo code JIMMY-BUFFETT-2015 for added savings. , Parrotheads in ... performer will be headlining at the Hollywood Bowl for ... be on Thursday, October 22nd and it will be ...
(Date:3/2/2015)... Doctors in Novara, Italy have found that ... outcomes for people with mesothelioma than other clinical factors. ... new study on the Surviving Mesothelioma website. , ... Piedmont followed the cases of 172 mesothelioma patients ... fluid. , “Persistent lung expansion after pleural talc ...
(Date:3/2/2015)... 2015 Burns Engineering's Lab-to-Lab Calibration ... Secondary Standard Platinum Resistance Thermometers (SSPRTs) and industrial ... or less . . . guaranteed. ... (Lab Code 200706-0), ISO 9001 and 17025 Certified ... is -196°C to 500°C, both ITS-90 and Callendar-van ...
(Date:3/2/2015)... The minimally invasive surgical instruments market is ... to reach $14,133.0 million by 2019 from $10,526.2 ... advantages of minimally invasive surgeries over traditional open ... surgeries and increasing number of surgical procedures among ... invasive surgical instruments market. , For More Details ...
Breaking Medicine News(10 mins):Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2
... In a decision of broad impact to medical malpractice ... refused to apply the state,s "cap" on non-economic damages ... when the Maryland General Assembly revised the damage cap ... could recover from negligent doctors and hospitals, the legislature ...
... April 21 Hudson Institute is pleased to welcome ... of Health and Human Services (HHS) under George W. ... Troy will write on health care, medical innovation, and ... around the corner, we are very fortunate to have ...
... Cancer Research,s 100th Annual Meeting 2009 -SOUTH SAN FRANCISCO, ... (Nasdaq: PARD ), a biopharmaceutical company focused ... from a Phase 1 clinical study of an oral ... showed that the bioavailability of oral picoplatin is nearly ...
... device for the treatment of depression named one ... 21 - NeuroStar(R) TMS (Transcranial Magnetic Stimulation) Therapy ... treatment cleared by the FDA for Major Depressive ... Design Excellence Award (MDEA). The award will be ...
... 21 Frost & Sullivan presented ... Pacific,s Healthcare sector at the 2009 Frost ... Awards held today at the InterContinental hotel in ... consecutive year, the awards banquet recognised companies across ...
... HRC ) fiscal 2009 second quarter earnings release will ... participate in a webcast the following morning on May 5, 2009 ... Holdings, Inc.,s Fiscal 2009 Second Quarter Release for the quarter ended ... NYSE close on Monday, May 4, 2009. The release will ...
Cached Medicine News:Health News:Judge Holds Maryland Damages Cap Not Applicable to Malpractice Cases 2Health News:Judge Holds Maryland Damages Cap Not Applicable to Malpractice Cases 3Health News:Former HHS Deputy Secretary Tevi Troy Joins Hudson Institute 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 3Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 4Health News:Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award 2Health News:Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award 3Health News:Outstanding Healthcare Companies in Asia Pacific Honored 2Health News:Outstanding Healthcare Companies in Asia Pacific Honored 3Health News:Outstanding Healthcare Companies in Asia Pacific Honored 4Health News:Outstanding Healthcare Companies in Asia Pacific Honored 5Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast 2
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Centra-GP6R general purpose centrifuges offer high-volume versatility ... rotor options, making them ideal for a ... Versatility , Four- or six-place sealed ... oil tube rotors offered , Lare capacity ...
... Centrifuges feature powerful, maintenance-free motors, ... of rotors for unparalleled application ... in one: a high capacity ... harvesting; a high-speed centrifuge for ...
... MicroCentrifuge Two Strip Rotor hold 16 0.2ml ... with). Simply close the polycarbonate lid to ... open. Starts and stops in seconds. Maximum ... g. Only five inches in diameter. Also ...
Medicine Products: